Literature DB >> 14745444

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Christopher G Willett1, Yves Boucher, Emmanuelle di Tomaso, Dan G Duda, Lance L Munn, Ricky T Tong, Daniel C Chung, Dushyant V Sahani, Sanjeeva P Kalva, Sergey V Kozin, Mari Mino, Kenneth S Cohen, David T Scadden, Alan C Hartford, Alan J Fischman, Jeffrey W Clark, David P Ryan, Andrew X Zhu, Lawrence S Blaszkowsky, Helen X Chen, Paul C Shellito, Gregory Y Lauwers, Rakesh K Jain.   

Abstract

The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745444      PMCID: PMC2693485          DOI: 10.1038/nm988

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  15 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

2.  Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.

Authors:  S Monestiroli; P Mancuso; A Burlini; G Pruneri; C Dell'Agnola; A Gobbi; G Martinelli; F Bertolini
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

3.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients.

Authors:  P Mancuso; A Burlini; G Pruneri; A Goldhirsch; G Martinelli; F Bertolini
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

Review 4.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

Authors:  Shahin Rafii; David Lyden; Robert Benezra; Koichi Hattori; Beate Heissig
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

Review 5.  Clinical translation of angiogenesis inhibitors.

Authors:  Robert Kerbel; Judah Folkman
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

Review 6.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 7.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

Authors:  Harold F Dvorak
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

8.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.

Authors:  F Yuan; Y Chen; M Dellian; N Safabakhsh; N Ferrara; R K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 9.  Angiogenesis in cancer and other diseases.

Authors:  P Carmeliet; R K Jain
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

10.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.

Authors:  C G Lee; M Heijn; E di Tomaso; G Griffon-Etienne; M Ancukiewicz; C Koike; K R Park; N Ferrara; R K Jain; H D Suit; Y Boucher
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

View more
  539 in total

1.  Effect of wall compliance and permeability on blood-flow rate in counter-current microvessels formed from anastomosis during tumor-induced angiogenesis.

Authors:  Peng Guo; Bingmei M Fu
Journal:  J Biomech Eng       Date:  2012-04       Impact factor: 2.097

2.  Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.

Authors:  Igor A Astsaturov; Neal J Meropol; R Katherine Alpaugh; Barbara A Burtness; Jonathan D Cheng; Sue McLaughlin; André Rogatko; Zhiheng Xu; James C Watson; Louis M Weiner; Steven J Cohen
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

3.  Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients.

Authors:  Seiya Saito; Naoko Hayashi; Nobutaka Sato; Masaaki Iwatsuki; Yoshifumi Baba; Yasuo Sakamoto; Yuji Miyamoto; Masayuki Watanabe; Minoru Yoshida; Kenji Sakai; Takashi Katsumori; Shigeru Katahuchi; Nobuyuki Shigaki; Kazutaka Yamada; Masami Kimura; Tomio Tanigawa; Sadamu Takano; Masafumi Kuramoto; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2012-06-05       Impact factor: 3.402

4.  Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.

Authors:  John F de Groot; Yuji Piao; Hai Tran; Mark Gilbert; Hua-Kang Wu; Jun Liu; B Nebiyou Bekele; Tim Cloughesy; Minesh Mehta; H Ian Robins; Andrew Lassman; Lisa DeAngelis; Kevin Camphausen; Alice Chen; W K A Yung; Michael Prados; Patrick Y Wen; John V Heymach
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 5.  [Oncological imaging for therapy response assessment].

Authors:  J Stattaus
Journal:  Radiologe       Date:  2014-01       Impact factor: 0.635

Review 6.  Lessons learned from the bevacizumab experience.

Authors:  Joanne Mortimer; Helene B Zonder; Sumanta K Pal
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

Review 7.  Rectal cancer treatment: improving the picture.

Authors:  Juan A Diaz-Gonzalez; Leire Arbea; Javier Aristu
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.

Authors:  Larissa Sweeny; Andrew Prince; Neel Patel; Lindsay S Moore; Eben L Rosenthal; Brian B Hughley; Jason M Warram
Journal:  Laryngoscope       Date:  2016-08-31       Impact factor: 3.325

9.  Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma.

Authors:  Ake Oldberg; Sebastian Kalamajski; Alexei V Salnikov; Linda Stuhr; Matthias Mörgelin; Rolf K Reed; Nils-Erik Heldin; Kristofer Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-22       Impact factor: 11.205

10.  Autocrine VEGF signaling is required for vascular homeostasis.

Authors:  Sunyoung Lee; Tom T Chen; Chad L Barber; Maria C Jordan; Jared Murdock; Sharina Desai; Napoleone Ferrara; Andras Nagy; Kenneth P Roos; M Luisa Iruela-Arispe
Journal:  Cell       Date:  2007-08-24       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.